Herbal medicinals: Selected clinical considerations focusing on known or potential drug-herb interactions

Archives of Internal Medicine

Volumn 158, Issue 20, 1998, Pages 2200-2211

  Miller, Lucinda G ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; AMIODARONE; ANABOLIC AGENT; CHAMOMILE; CYCLOSPORIN; DIGOXIN; DIURETIC AGENT; ECHINACEA EXTRACT; GINKGO BILOBA EXTRACT; HERBACEOUS AGENT; IMMUNOSTIMULATING AGENT; IMMUNOSUPPRESSIVE AGENT; KETOCONAZOLE; KYUSHIN; METHOTREXATE; MONOAMINE OXIDASE INHIBITOR; NONSTEROID ANTIINFLAMMATORY AGENT; SEROTONIN UPTAKE INHIBITOR; TANNIN; UNINDEXED DRUG; VALERIAN; WARFARIN;

CRATAEGUS; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG INTERACTION; DRUG MECHANISM; DRUG POTENTIATION; FUCUS; GARLIC; GINSENG; GLYCYRRHIZA; HERBAL MEDICINE; HORMONE SUBSTITUTION; HUMAN; HYPERICUM PERFORATUM; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SABAL; SEIZURE; SEROTONINERGIC SYSTEM; TANACETUM PARTHENIUM;

DRUG INTERACTIONS; HERB-DRUG INTERACTIONS; HUMANS; PHYTOTHERAPY; PLANT EXTRACTS; PLANTS, MEDICINAL;

EID: 0032501120     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.158.20.2200     Document Type: Review

References (171)

1. Richman A, Witkowski J. Herbs by the numbers. Whole Foods Magazine. 1997:20, 22, 24, 26, 28.
2. Johnston BA. One-third of nation's adults use herbal remedies. Herbalgram. 1997;40:49.
3. Eisenberg DM, Kessler RC, Foster C, Norlock FE, Calkins DR, Delbanco TL. Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med. 1993;328:246-252.
4. Newall CA, Anderson LA, Phillipson JD. Chamomile monograph. In: Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicinals: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1996:69-73.
5. Mann C, Staba EJ. The chemistry, pharmacology and commercial formulations of chamomile. In: Craker LE, Simon JE, eds. Herbs, Spices and Medicinal Plants: Recent Advances in Botany, Horticulture and Pharmacology. Vol 1. Binghamton, NY: Hayworth Press Inc; 1986:235-280.
6. Casterline CL. Allergy to chamomile tea. JAMA. 1980;4:330-331.
7. Benner MH, Lee HJ. Anaphylactic reaction to chamomile tea. J Allergy Clin Immunol. 1973;52:307-308.
8. Robbers JE, Speedie MK, Tyler VE. Terpinoids. In: Robbers JE, Speedie MK, Tyler VE, eds. Pharmacognosy and Pharmacobiotechnology. Baltimore, Md: Williams & Wilkins; 1996:80-107.
9. Bauer R, Khan IA, Wray V, Wagner H. Structure and stereochemistry of new sesquiterpene esters from Echinacea purpurea. Helv Chim Acta. 1985;68:2355-2358.
10. Wagner H, Suppner H, Schafer W, Zenk M. Immunologically active polysaccharides of Echinacea purpurea cell cultures. Phytochemistry. 1988;27:119-126.
11. Tubaro A, Tragni E, DelNegro P, Galli CL, Loggia RD. Anti-inflammatory activity of a polysaccharidic fraction of Echinacea angustifolia. J Pharm Pharmacol. 1987;39:567-569.
12. Stimpel M, Proksch A, Wgner H, Lohmann-Matthes ML. Macrophage activation and induction of macrophage cytotoxicity b purified polysaccharide fractions from the plant Echinacea purpurea. Infect Immun. 1984;46:845-849.
13. Parnham MJ. Benefit-risk assessment of the squeezed sap of the purple coneflower (Echinacea purpurea) for long-term oral immunostimulation. Phytomedicine. 1996;3:95-102.
14. Blumenthal M, Gruenwald J, Hall T, Riggins R, Rister R, eds. German Commission E Monographs: Therapeutic Monographs on Medicinal Plants. Austin, Tex: American Botanical Council; 1998.
15. Johnson ES, Kadam NP, Hylands DM, Hylands PJ. Efficacy of feverfew as prophylactic treatment of migraine. BMJ. 1985;291:569-573.
16. Murphy JJ, Heptinstall S, Mitchell JRA. Randomized, double-blind, placebo-controlled trial of feverfew in migraine prevention. Lancet. 1988;2:189-192.
17. Collier JOH, Butt NM, McDonald-Gibson WJ, Saeed SA. Extract of feverfew inhibits prostaglandin biosynthesis. Lancet. 1980;2:922-923.
18. Newall CA, Anderson LA, Phillipson JD. Feverfew monograph. In: Newall CA, Anderson IA, Phillipson JD, eds. Herbal Medicinals: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1996:119-121.
19. Hepinstall S, Awang DV, Dawson BA, Kindach K, Knight DW, May J. Parthenolide content and bioactivity of feverfew: estimates of commercial and authenicated feverfew products. J Pharm Pharmacol. 1992;44:391-395.
20. Baldwin CA, Anderson LA, Phillipson JD. What pharmacists should know about feverfew. J Pharm Pharmacol. 1987;239:237-238.
21. Heptinstall S, Groenewegen WA, Spangenberg P, Loesche W. Extracts of feverfew may inhibit platelet behavior via neutralization of sulphydryl groups. J Pharm Pharmacol. 1987;39:459-465.
22. Makheja AN, Bailey J. The active principle in feverfew [letter]. Lancet. 1981;2:1054.
23. Reuter HD. Allium sativum and Allium ursinum, part 2: pharmacolocy and medicinal applications. Phytomedicine. 1995;2:73-91.
24. Foushee DB, Ruffin J, Banerjee U. Garlic as a natural agent for the treatment of hypertension: a preliminary report. Cytobios. 1982;34:145-152.
25. Malik ZA, Siddiqui S. Hypotensive effect of freeze-dried garlic sap in dog. J Pak Med Assoc. 1981; 31:12-13.
26. Ruffin J, Hunter SA. An evaluation of the side effects of garlic as an antihypertensive agent. Cytobios. 1983;37:85-89.
27. Kleijnen J, Knipschild P, Riet GT. Garlic, onions and cardiovascular risk factors: a review of the evidence from human experiments with emphasis on commercially available prepartions. Br J Clin Pharmacol. 1989;28:535-544.
28. Bleumink E, Doeglas HMG, Klokke AH, Nater JP. Allergic contact dermatitis to garlic. Br J Dermatol. 1972;87:6-9.
29. Silagy CA, Neil AW. A meta-analysis of the effect of garlic on blood pressure. J Hypertens. 1994;12:463-468.
30. Aue W, Eiber W, Hertkorn E, et al. Hypertension and hyperlipidemia: garlic helps in mild cases. Br J Clin Pract. 1990;69(suppl): 3-6.
31. Neil HAW, Silagy CA, Lancaster T, et al. Garlic powder in the treatment of moderate hyperlipidemia: a controlled trial and meta-analysis. J R Coll Physician. 1996;30:329-334.
32. Dixit VP, Joshi S. Effects of chronic administration of garlic (Allium sativum Linn) on testicular function. Indian J Exp Biol. 1982;20:534-536.
33. Cooperative Group for Essential Oil of Garlic. The effect of essential oil of garlic on hyperlipidemia and platelet aggregation: an analysis of 308 cases. J Tradit Chin Med. 1986;6:117-120.
34. Bordia A. Effect of garlic on human platelet aggregation in vitro. Atherosclerosis. 1978;30: 355-360.
35. Rose KD, Croissant PD, Parliament CF, Levin MP. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery. 1990; 26:880-882.
36. Grontved A, Hentzer E. Vertigo-reducing effect of ginger root. J Otolaryngol. 1986;48:282-286.
37. Mowrey DB, Clayson DE. Motion sickness, ginger and psychophysics. Lancet. 1982;1:655-657.
38. Holtmann S, Clarke AH, Scherer H, Hohn M. The anti-motion sickness mechanism of ginger. Acta Otolaryngol (Stockh). 1989;108:168-174.
39. Bone ME, Wilkinson DJ, Young JR, et al. Ginger root: a new antiemetic: the effect of ginger root on postoperative nausea and vomiting after major gynecological surgery. Anesthesia. 1990;45:669-671.
40. Grontved A, Brask T, Kambskard J, Hentzer E. Ginger root against seasickness: a controlled trial on the open sea. Acta Otolaryngol (Stockh). 1988; 105:45-49.
41. Fischer-Rasmussen W, Kjaer SK, Dahl C, Asping U. Ginger treatment of hyperemesis gravidarum. Eur J Obstet Gynecol Reprod Biol. 1990;38:19-24.
42. Nakamura H, Yamamoto T. Mutagen and antimutagen in ginger: Zingiber officinale. Mutat Res. 1982;109:119-126.
43. Nakamura H, Yamamoto T. The active part of the (6)-gingerol in mutagenesis. Mutat Res. 1983; 122:87-94.
44. Backon J. Ginger: inhibition of thromboxane synthetase and stimulation of prostacyclin: relevance for medicine and psychiatry. Med Hypothesis. 1986;20:271-278.
45. Cott J. Natural product formulations available in Europe for psychotropic indication. Psychopharmacol Bull. 1995;31:745-751.
46. Sastre J, Millan A, de la Asuncion G, et al. A Ginkgo biloba extract (Egb 761) prevents mitochondrial aging by protecting against oxidative stress. Free Radic Bio Med. 1998;24:298-304.
47. Benzi G, Moretti A. Are reactive oxygen species involved in Alzheimer's disease? Neurobiol Aging. 1995;16:661-674.
48. LeBars PL, Katz MM, Berman N, et al. A placebo-controlled, double-blind, randomized trial of an extract of Ginkgo biloba for dementia. JAMA. 1997;278:1327-1332.
49. Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract [letter]. N Engl J Med 1997;336:1108.
50. Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion have also occurred. Neurology. 1996;46:1775-1776.
51. Chung KF, McCusker M, Page CP, Dent G, Guinoit P, Barnes PJ. Effect of ginkgolide mixture in amagonizing skin and platelet responses to platelet activating factor in man. Lancet. 1987;1:248-251.
52. Arenz A, Klein M, Fiehe K, et al. Occurrence of neurotoxic 4′-o-methylpyridoxine in Ginkgo biloba leaves, Ginkgo medications and Japanese Ginkgo food. Planta Med. 1996;62:548-551.
53. Vorberg G. Ginkgo biloba extract: a long-term study of chronic cerebral insufficiency in geriatric patients. Clin Trials J. 1985;22:149-157.
54. Lui J, Staba EJ. The ginsenosides of various ginseng plants and selected products. J Nat Prod. 1989; 43:34-36.
55. McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. CMAJ. 1996;155:293-295.
56. Liberti LE, Marderosian AD. Evaluation of commercial ginseng products. J Pharm Sci. 1978; 10:1487-1489.
57. Ng TB, Li WW, Yeung HW. Effects of ginsenosides, lectins and Momordica charantia insulin-like peptide on corticosterone production by isolated rat adrenal cells. J Ethnopharmacol. 1987; 21:21-29.
58. Jie YH, Cammisuli S, Baggiolini M. Immunomodulatory effects of Panax ginseng: CA Meyer in the mouse. Agents Actions Suppl. 1984;15:386-391.
59. Singh VK, Agarwal SS, Gupta BM. Immunomodulatory activity of Panax ginseng extract. Planta Med. 1984;50:462-465.
60. Sotaniemi EA, Haapakkoski E, Rautio A. Ginseng therapy in non-insulin-dependent diabetic patients. Diabetes Care. 1995;18:1373-1375.
61. Yokozawa T, Kobayashi T, Oura H, Kawashima Y. Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb2 in streptozotocin-diabetic rats. Chem Pharm Bull. 1985;33:869-872.
62. Oshima Y, Kkonno C, Hikino H. Isolation and hypoglycemic activity of panaxans I, J, K and L, glycans of Panax ginseng roots. J Ethnopharmacol. 1985;14:255-259.
63. Konno C, Murakami M, Oshima Y, Hikino H. Isolation and hypoglycemic activity of panaxans Q,R,S,R and U: glycans of Panaxginseng roots. J Ethnopharmacol. 1985;14:69-74.
64. Konno C, Sugiyama K, Kano M, Takahashi M, Hikino H. Isolation and hypoglycemic activity of panaxans A, B, C, D and E: glycans of Panax ginseng roots. Planta Med. 1984;50:436-438.
65. Tokmoda M, Shimada K, Kkonno C, Sugiyama K, Hikino H. Partial structure of panaxan A: a hypoglycemic glycan of Panax ginseng roots. Planta Med. 1984;50:436-438.
66. Baldwin CA. What pharmacists should know about ginseng. Pharm J. 1986;237:583-586.
67. Hammond TG, Whitworth JA. Adverse reactions to ginseng [letter]. Med J Aust. 1981;1:492.
68. Dega H, Laporte J, Frances C, Herson S, Choisidow O. Ginseng as a cause for Stevens-Johnson syndrome [letter]? Lancet. 1996;347:1344.
69. Greenspan EM. Ginseng and vaginal bleeding [letter]. JAMA. 1983;249:2018.
70. Hopkins MP, Androff L, Benningnoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol. 1988;159:1121-1122.
71. Palmer BV, Montgomery ACV, Monteriro JCMP. Ginseng and mastalgia. BMJ. 1978;1:1284.
72. Koren G. Maternal use of ginseng and neonatal androgenization [letter]. JAMA. 1991;265:1828.
73. Awang DVS. Maternal use of ginseng and neonatal androgenization [letter]. JAMA. 1991;265;1828.
74. Waller DP, Martin AM, Farnswort NR, Awang DVC. Lack of androgenicity of Siberian ginseng [letter]. JAMA. 1992;267:2329.
75. Janetzky K, Morreale AP. Probable interactions between warfarin and ginseng. Am J Health Syst Pharm. 1997;54:692-693.
76. Kuo SC, Teng CM, Lee JG, Ko FN, Chen SC, Wu TS. Antiplatelet components in Panax ginseng. Planta Med. 1990;56:164-167.
77. Shader RI, Greenblatt DJ. Phenelzine and the dream machine-ramblings and reflections [editorial]. J Clin Psychopharmacol. 1985;5:65.
78. Jones BD, Runikis AM. Interactions of ginseng with phenelzine. J Clin Psychopharmacol. 1987;7:201-202.
79. Siegel RK. Ginseng abuse syndrome. JAMA. 1979;241:1614-1615.
80. Elghamry MI, Hansel R. Activity and isolated phytoestrogen of shrub palmetto fruits (Serenoa repens Small): an estrogenic plant. Experientia. 1969;24:828-829.
81. Sultan C. Inhibition of androgen metabolism and binding by a liposterolic extract of Serenoa repens B in human foreskin fibroblasts. J Steroid Biochem Mol Biol. 1984;20:515-519.
82. Champault G, Patel JC, Bonnard AM. A double-blind trial of an extract of the plant Serenoa rerpens in benign prostatic hyperplasia. Br J Clin Pharmacol. 1984;18:461-462.
83. Tasca A. Treatment of obstruction in prostatic adenoma using an extract of Serenoa repens: double-blind clinical test vs placebo. Minerva Urol Nefrol. 1985;37:887-891.
84. Bach D, Schmitt M, Ebeling L. Phytopharmaceutical and synthetic agents in the treatment of benign prostatic hyperplasia (BPH). Phytomedicine. 1997;3-4:209-213.
85. Lohse MJ, Muller-Oerlinghausen B. Psychopharmaka. In: Schwabe U, Pffrath D, eds. Arzeiverordnungreport '94. Stuttgart, Germany: Gustav Fischer; 1994:354-370.
86. Wagner H, Bladt S. Pharmaceutical quality of Hypericum extracts. J Geriatr Psychiatry Neurol. 1994;7(suppl 1):65-68.
87. Sparenberg B, Demisch L, Holzl J. Investigations of the antidepressive effects of St. John's wort. Pharm Ztg Wiss. 1993:6P50-54.
88. Bladt S, Wagner H. Inhibition of MAO by fractions and constituents of Hypericum extract. J Geriatr Psychiatry Neurol. 1994;(suppl 1):S57-S59.
89. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D. St John's wort for depression: an overview and meta-analysis of randomized clinical trials. BMJ. 1993;313:253-258.
90. McGuffin M, Hobbs C, Upton R, Goldberg A, eds. Botanical Safety Handbook. New York, NY: CRC Press Inc; 1997:62-63.
91. Leathwood PD, Chauffard F. Aqueous extract of valerian reduces latency to fall asleep in man. Planta Med. 1985;51:144-148.
92. Leathwood PD, Chauffard F, Heck E, Munoz-Box R. Aqueous extract of valerian root improves sleep quality in man. Pharmacol Biochem Behav. 1982;17:65-71.
93. Balderer G, Borbely AA. Effect of valerian on human sleep. Psychopharmacology (Berl). 1985; 87:406-409.
94. Brown D. Valerian: clinical overview. Townsend Lett Doctors. 1995:150-51.
95. Hiller KO, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L: behavioural and anticonvulsant activities. Physiother Res Int. 1996;10:145-151.
96. Capasso A, DeFeo V, DeSimon F, Sorrentino L. Pharmacological effects of aqueous extracts from Valeriana adscendens. Physiother Res Int. 1996; 10:309-312.
97. Food and Drug Administration. FDA warns consumers against dietary supplement products that may contain digitalis mislabeled as plantain. June 12, 1997.
98. Blumenthal M. Industry alert: plantain adulterated with digitalis. HerbalGram. 1997;40:28-29.
99. Evans WC. Saponins, cardioactive drugs and other steroids. In: Evans WC, ed. Pharmacognosy. 14th ed. Philadelphia, Pa: WB Saunders Co; 1996:293-321.
100. Wash LK, Bernard JD. Licorice-induced pseudoaldosteronism. Am J Hosp Pharm. 1975;32:73-74.
101. Walker BR, Edwards CRW. Licorice-induced hypertension and syndromes of apparent mineralocorticoid excess. Endocrinol Metab Clin North Am. 1994;23:359-377.
102. Stewart PM, Wallace AM, Valentine R, Burt D, Shackleton CHL, Edwards CRW. Mineralocorticoid activity of liquorice: 11-beta-hydroxysteroid dehydrogenase deficiency comes of age. Lancet. 1987;2:821-824.
103. Gomez-Sanchez EP, Gomez-Sanchez CE. Central hypertensivnogenic effects of glycyrrhizic acid and carbenoxolone. Am J Physiol. 1992;236: 1125-1130.
104. Farese RV, Biglieri EG, Shackleton CHL, Rony I, Gomez-Fontes R. Licorice-induced hypermineralocorticoidism. N Engl J Med. 1991;325:1223-1227.
105. Salassa RM, Mattox VR, Rosevear JW. Inhibition of the mineralocorticoid activity of licorice by spironolactone. J Clin Endocrinol Metab. 1962; 22:1156-1159.
106. Corse FM, Galgani S, Gasparini C, Piazza G. Acute hypokalemic myopathy due to chronic licorice ingestion: report of a case. J Neurol Sci. 1983; 4:493-497.
107. Fushimi R, Tachi J, Amino N, Myiai K. Chinese medicine interfering with digoxin immunoassays [letter]. Lancet. 1989;1:339.
108. Suga T. Chemistry and pharmacology of Chansu, Taisha. Chin Med J (Engl). 1973:suppl 10: 762-773.
109. Schliche H, ed. Phytotherapy in Paediatrics: Handbook for Physicians and Pharmacists. Stuttgart, Germany: Medpharm GmbH Scientific Publishers; 1997:143.
110. Hobbs C, Foster S. Hawthorn: a literature review. HerbalGram 1990;22:19-33.
111. Racz-Kotilla E. Hypotensive and beta-blocking effect of procyanidins of Crataegus monogyna. Planta Med. 1980;39:239-241.
112. Bisset NG, ed. Herbal Drugs and Phytopharmaceuticals: A Handbook for Practice on a Scientific Basis. Stuttgart, Germany: Medpharm GmbH Scientific Publishers; 1994:46,441.
113. Newall CA, Anderson LA, Phillipson JD. Evening primrose monograph. In: JD Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1997:110-113.
114. Barber JH. Evening primrose oil: a panacea? Pharm J. 1988;240:723-725.
115. Newall CA, Anderson LA, Phillipson JD. Borage monograph. In: Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1997:49.
116. Hoffman D. The Herb Users Guide: The Basic Skills of Medical Herbalism. Wellingborough, England: Thorsons; 1987.
117. Mills DE. Dietary fatty acid supplementation alters stress reactivity and performance in man. J Hum Hypertens. 1989;3:111-116.
118. Larsen L. Unsaturated pyrrolizidines from Borage (Borage officinalis) a common garden herb. J Nat Prod. 1984;45:747-748.
119. Dandekar UP, Chandra RS, Dalvi SS, et al. Analysis of a clinically important interaction betwween phenytoin and Shankhapulshpi, an Ayurvedic preparation. J Ethnopharmacol. 1992;35: 285-288.
120. Swinyard EA. Woodhead JH. Experimental detection quantification and evaluation of anticonvulsants. In: Woodbury DM, Penry JK Pippenger CE, eds. Antiepileptic Drugs. New York, NY: Raven Press; 1982:111-126.
121. Lo ACT, Chan K, Yeung JHK, Woo KS. The effects of danshen on pharmacokinetics and pharmacodynamics of warfarin rats. Eur J Drug Metab Pharmacokinet. 1992;17:257-262.
122. Newall CA, Anderson LA, Phillipson JD. German chamomile monograph. In: Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1997: 69-71.
123. Sumner H, Salan U, Knight DW, Hoult JR. Inhibition of 5-lipoxygenase and cyclo-oxygenase in leukocytes by feverfew: involvement of sesquiterpene lactones and other components. Biochem Pharmacol. 1992;43:2313-2320.
124. Gorenewegen WA, Heptininstall S. A comparison of the effects of an extract of feverfew and parthenolide, a component of feverfew, on platelet activity in-vitro. J Pharm Pharmacol. 1990; 42:553-557.
125. Biggs MJ, Johnson EW, Persaud NP, Ratcliffe DM. Platelet aggregation in patients using feverfew for migraine [letter]. Lancet. 1982;2;776.
126. Duffield PH, Jamieson D. Development of tolerance to kava in mice. Clin Exp Pharmacol Physiol. 1991;18:571-578.
127. Ruzo P. Kava-induced dermatopathy: a niacin deficiency? Lancet. 1990;335:1442-1445.
128. Norton SA, Ruze P. Kava dermopathy. J Am Acad Dermatol. 1994;31:89-97.
129. Jamieson DD, Duffield PH. Positive interaction of ethanol and kava resin in mice. Clin Exp Pharmacol Physiol. 1990;17:509-514.
130. Davies LP, Drew CA, Duffield P, Johnston GA, Jamieson DD. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol. 1992; 71:120-126.
131. Davies LP, Drew CA, Duffield P. Kava pyrones and resin: studies on GABAA, GABAB and benzodiazepine binding sites in rodent brain. Pharmacol Toxicol. 1992;71:120-126.
132. Jussofie A, Schmiz A, Hiemke C. Kavapyrone-enriched extract from Piper methysticum as modulator of GABA binding sites in different regions of rat brain. Psychopharmacology (Berl). 1994;116:469-474.
133. Almeida JC, Grimsley EW. Coma from the health food store: interaction between kava and alprazolam. Ann Intern Med. 1996;125:940-941.
134. Stimpel M, Proksch A, Wagner H, Lohmann-Matthes ML. Macrophage activation and induction of macrophage cytotoxicity by purified polysaccharide fractions from the plant Echinacea purpurea. Infection Immun. 1984;46:845-849.
135. See DM, Broumand N, Sahl T, Tilles J. In vitro effects of echinacea and ginseng on natural killer and antibody dependent cell cytotoxicity in healthy subjects and chronic fatigue syndrome or acquired immunodeficiency syndrome patients. Immunopharmacology. 1997;35:229-235.
136. Jin R, Wan LL, Mitsuishi T. Effects of shi-ka-ma and Chinese herbs in mice treated with antitumor agent mitocycin C. Chung Kuo Chung Hsi I Chieh Ho Tsa Chih. 1995;15:101-103.
137. Utsunomiya T, Kobayashi M, Pollard RB, Suzuki F. Glycyrrhizin, an active component of licorice roots, reduces morbidity and mortality in mice infected with lethal doses of influenza virus. Antimicrob Agents Chemother. 1997;41:551-556.
138. Dinnen RD, Ibibuzaki K. The search for novel anticancer agents: a differentiation-based assay and analysis of a folklore product. Anticancer Res. 1997;17:1027-1033.
139. Herbert V, Kasdan TS. Alfalfa, vitamin E, and autoimmune disorders. Am J Clin Nutr. 1994;60: 639-640.
140. Mossad SB, Macknin ML, Medendorp SV, Mason P. Zinc gluconate lozenges for treating the common cold. Ann Intern Med. 1996;125:81-88.
141. Salas M, Kirchner H. Induction of interferon-gamma in human leukocyte cultures stimulated by Zn2±. Clin Immunol Immunopathol. 1987; 45:139-142.
142. Korant BD, Butterworth BE. Inhibition by zinc of rhinovirus protein cleavage: interaction of zinc with capsid polypeptides. J Virol. 1976;18:298-306.
143. Gesits FC, Bateman JA, Hayden FG. In vitro activity of zinc salts against human rhinoviruses. Antimicrob Agents Chemother. 1987;31:622-624.
144. Tyler V. Kidney, urinarytractand prostate problems. In: Tyler V, ed. Herbs of Choice. Binghamton, NY: Pharmaceutical Products Press Inc; 1994:73-86.
145. Newall CA, Anderson LA, Phillipson JD. Diuretic herbal ingredients. In: Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1997:281.
146. Olin BF, ed. Gossypol monograph. Lawrence Review of Natural Products. St Louis, Mo: Facts and Comparisons Inc; 1998.
147. Lin YC, Fukaya T, Rikihisa Y, Walton A. Gossypol in female fertility control: ovum implantation and early pregnancy inhibited in rats. Life Sci. 1985;37:39-47.
148. Liu Z, Hinton E, Cao J, Zhu C, Li B. Effects of potassium salt or a potassium blocker on gossypol-related hypokalemia. Contraception. 1988;37:111-117.
149. Pizarro F, Olivares M, Hertrampf E, Walter T. Factors which modify the nutritional state of iron: tannin content of herbal teas. Arch Latinoam Nutr. 1994;44:277-280.
150. Newall CA, Anderson LA, Phillipson JD. Horse-radish monograph. In: Newall CA, Anderson LA, Phillipson JD, eds. Herbal Medicines: A Guide for Health-Care Professionals. London, England: Pharmaceutical Press; 1997:168.
151. Anonymous. Kelp diets can produce myxedema in iodide-sensitive individuals. JAMA. 1975;233:9-10.
152. Shilo S, Hirsch HJ. Iodine-induced hyperthyroidism in a patient with a normal thyroid gland. Postgrad Med J. 1986;62:661-662.
153. Waller DP, Zaveveld LJD, Farnsworth NR. Gossypol: pharmacology and current status as a male contraceptive. In: Wagner H, Hikino H, Farnsworth NR, eds. Economic and Medicinal Plant Research. London, England: Academic Press Inc; 1985:87-112.
154. De Smet PAGM. Adverse Reactions of Herbal Drugs. Vol 2. New York, NY: Springer-Verlag NY Inc; 1993.
155. De Smet PAGM. Adverse Reactions of Herbal Drugs. Vol 3. New York, NY: Springer-Verlag NY Inc; 1997.
156. De Smet PAGM. Adverse Reactions of Herbal Drugs. Vol 1. New York, NY: Springer-Verlag NY Inc; 1992.
157. d'Arcy PF. Adverse reactions and interactions with herbal medicines: part 2. ADR Toxicol Rev. 1992; 12:147-162.
158. De Smet PAGM, Nolen WA. St John's wort as an antidepressant. BMJ. 1996;313:241-242.
159. Duke JA. Commentary-novel psychotherapeutic drugs: a role for ethnobotany. Psychopharmacol Bull. 1995;31:177-182.
160. Reynolds JEF, ed. Martindale: The Extra Pharmacopoeia. 29th ed. London, England: Pharmaceutical Press; 1989.
161. Gomez-Sanchez CE, Gomez-Sanchez CE, Yamakita N. Endocrine causes of hypertension. Semin Nephrol. 1995;15:1-15.
162. Blachley JD, Knochel JP. Tobacco chewer's hypokalemia: licorice revisited. N Engl J Med. 1980; 302:74-75.
163. Beretta-Piccoli C, Salvade G, Crivelli PL, Weidmann P. Body sodium and blood volume in a patient with licorice-induced hypertension. J Hypertens. 1985; 3:19-23.
164. Leatherdale BA, Panesar RK, Singh G, Atkins TW, Bailery CJ, Bignell AHC. Improvement in glucose tolerance due to Momordica charantia (karela). BMJ. 1981;282:1823-1824.
165. Gupta SS, Seth CB. Effect of Momordica charantia linn (karela) on glucose tolerance in albino rats. J Indian Med Assoc. 1962;39:581-584.
166. Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide) [letter]. Lancet. 1979;1:7607.
167. Anderson RA. Chromium, glucose tolerance and diabetes. Biol Trace Elem Res. 1992;32:19-24.
168. Lee NA, Reasner CA. Beneficial effect of chromium supplementation on serum triglyceride levels in NIDDM. Diabetes Care. 1994;17:1449-1452.
169. Kincheloe L. Gynecological and obstetric concerns regarding herbal medicinal use. In: Miller LG, Murray WJ, eds. Herbal Medicinals: A Clinician's Guide. Binghamton, NY: Pharmaceutical Products Press; 1998:285-314.
170. Costello C. Estrogenic substances from plants. J Am Pharm Assoc (Wash). 1950;39:177-180.
171. Holt S. Phytoestrogens fora healthier menopause. Altern Ther Health Med. 1997;1:187-193.